- Home
- JFU vs ABVC Comparison
JFU vs ABVC Comparison
Compare JFU & ABVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JFU | ABVC |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.6M | 34.6M |
| IPO Year | 2018 | 2009 |
Fundamental Metrics
Financial Performance| Metric | JFU | ABVC |
|---|---|---|
| Price | $2.47 | $1.03 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.5K | ★ 109.1K |
| Earning Date | 12-09-2022 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.14 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $509,589.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.43 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.58 | $0.88 |
| 52 Week High | $9.48 | $3.39 |
Technical Indicators
Market Signals| Indicator | JFU | ABVC |
|---|---|---|
| Relative Strength Index (RSI) | 51.59 | 38.55 |
| Support Level | $2.00 | $0.96 |
| Resistance Level | $2.88 | $1.15 |
| Average True Range (ATR) | 0.12 | 0.09 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 62.19 | 18.62 |
Price Performance
Historical ComparisonAbout JFU 9F Inc.
9F Inc is a digital technology and wealth management service provider aiming to empower institutional partners with financial technologies as well as attract investors with investment opportunities that come with the vast potential of China's new consumer economy and the appreciation of world-wide assets and access to quality products at a competitive price. The Company's operations are organized into segments, consisting of E-commerce services, technology Empowerment service, and Wealth Management services.
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants. It currently has six drugs and three medical devices in development. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. Its products include: Vitargus - ABV-1701, ABV-2001, ABV-2002, MDD ABV-1504, ADHD ABV-1505, ADHD ABV-1601, ABV-1501, ABV-1702, and ABV-1703.